Differential drug response in pulmonary arterial hypertension: The potential for precision medicine.
Differential drug response in pulmonary arterial hypertension: The potential for precision medicine.
复制标题
DOI：
10.1002/pul2.12304
复制
发表时间：
2023-10
影响因子：
2.6
通讯作者：
Karnes, Jason H.
中科院分区：
文献类型：
--
作者：
Miller, Elise;Sampson, Chinwuwanuju Ugo-Obi;Desai, Ankit A.;Karnes, Jason H.
肺动脉高压（PAH）是一种罕见、复杂且致命的心肺疾病。其特点是肺动脉内皮细胞功能改变和平滑肌细胞增殖，引起持续性血管收缩，导致右心肥厚和衰竭。有多种针对 PAH 治疗的药物类别，但患者之间的差异可能会影响治疗反应。一小部分患者对肺血管扩张剂有反应，可以用钙通道阻滞剂治疗，但如果给典型的 PAH 患者开处方，这将是有害的。对于血管反应性 PAH 患者中这种重要差异的根本原因知之甚少。性别、种族/民族和药物基因组学也可能影响 PAH 特异性药物的功效和安全性。研究表明，内皮素受体拮抗剂可能对女性更有效，并且在某些种族和民族中发现了一些细微的差异，但这些发现因社会经济因素的影响以及临床试验中缺乏非白人患者的代表性而变得混乱。 CYP3A5、CYP2C9、PTGIS、PTGIR、GNG2、CHST3 和 CHST13 等基因的遗传变异可能会影响某些 PAH 特异性药物的疗效和安全性。 PAH 研究面临许多挑战，但新方法有可能为 PAH 的发展和治疗提供新的见解。
Pulmonary arterial hypertension (PAH) is a rare, complex, and deadly cardiopulmonary disease. It is characterized by changes in endothelial cell function and smooth muscle cell proliferation in the pulmonary arteries, causing persistent vasoconstriction, resulting in right heart hypertrophy and failure. There are multiple drug classes specific to PAH treatment, but variation between patients may impact treatment response. A small subset of patients is responsive to pulmonary vasodilators and can be treated with calcium channel blockers, which would be deleterious if prescribed to a typical PAH patient. Little is known about the underlying cause of this important difference in vasoresponsive PAH patients. Sex, race/ethnicity, and pharmacogenomics may also factor into efficacy and safety of PAH‐specific drugs. Research has indicated that endothelin receptor antagonists may be more effective in women and there have been some minor differences found in certain races and ethnicities, but these findings are muddled by the impact of socioeconomic factors and a lack of representation of non‐White patients in clinical trials. Genetic variants in genes such as CYP3A5, CYP2C9, PTGIS, PTGIR, GNG2, CHST3, and CHST13 may influence the efficacy and safety of certain PAH‐specific drugs. PAH research faces many challenges, but there is potential for new methodologies to glean new insights into PAH development and treatment.
登录
查看更多内容
较低的DHEA-S水平可以预测特发性，结缔组织疾病和先天性心脏病相关的肺动脉高压的绝经后妇女的疾病和恶化。
DOI：
10.1183/13993003.00467-2018
发表时间：
2018-06
期刊：
The European respiratory journal
影响因子：
--
作者：
Baird GL;Archer-Chicko C;Barr RG;Bluemke DA;Foderaro AE;Fritz JS;Hill NS;Kawut SM;Klinger JR;Lima JAC;Mullin CJ;Ouyang P;Palevsky HI;Palmisicano AJ;Pinder D;Preston IR;Roberts KE;Smith KA;Walsh T;Whittenhall M;Ventetuolo CE
通讯作者：
Ventetuolo CE
影响因子：
37.8
作者：
Elliott, C. Gregory;Glissmeyer, Eric W.;Ward, Kenneth
通讯作者：
Ward, Kenneth
影响因子：
5.8
作者：
通讯作者：
--
肺动脉高压的药理治疗：探索药物基因组学。
影响因子：
1.7
作者：
Duarte JD;Hanson RL;Machado RF
通讯作者：
Machado RF
影响因子：
37.8
作者：
Fayyaz AU;Edwards WD;Maleszewski JJ;Konik EA;DuBrock HM;Borlaug BA;Frantz RP;Jenkins SM;Redfield MM
通讯作者：
Redfield MM